MedTrace Logo

Metabolic Profile and Anthropometric Changes in Schizophrenia

NCT00534183 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2006

Last updated 2007-09-24

No results posted yet for this study

Summary

"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "

Conditions

Interventions

DRUG

Olanzapine

Olanzapine in dose range of 10-20mg

DRUG

Risperidone

Risperidone 1-6mg

DRUG

Haloperidol

Haloperidol 10-20mg

Sponsors & Collaborators

  • Central Institute of Psychiatry, Ranchi, India

    lead OTHER

Principal Investigators

  • Sahoo Saddichha, DPM · Central Institute of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Completion
2006-12-31

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00534183 on ClinicalTrials.gov